« Return to News | Drug Sponsors

Aveo Oncology to restructure, cut workforce 62%

Friday, June 7, 2013 01:47 PM

Aveo Oncology, a cancer therapeutics company, is restructuring to refocus its efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advance key pipeline and preclinical assets. This restructuring is expected to extend the company's cash runway for at least two years, beyond anticipated data read-outs from ongoing trials of tivozanib and AV-203.

"As a result of the recent ODAC meeting, we believe it is likely that tivozanib will not receive FDA approval for renal cell carcinoma or RCC," said William J. Slichenmyer, M.D., chief medical officer of Aveo. "With the decision of our partner, Astellas, not to proceed with a European filing for tivozanib or financially support future clinical trials in RCC, Aveo has no plans at this time to pursue tivozanib development in RCC."

"The company intends to focus its R&D efforts on areas in oncology where the insights derived from Aveo's proprietary Human Response Platform will allow the development of targeted agents with the potential to provide substantial clinical benefit for specific biomarker-defined patient populations that could enable a clear regulatory pathway to approval," said Tuan Ha-Ngoc, president and CEO of Aveo.

Aveo's restructuring will eliminate approximately 140 positions, or 62% of Aveo's workforce.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.